Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
Effects on survival in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was reported in The Lancet, and demonstrate that reductions in disease-specific mortality in this randomized control trial (RCT) indicate that ovarian cancer screening works. The UKCTOCS was large enough for sufficient accrual and follow-up, using two intervention arms: MMS (a multimodal strategy using the biomarker Ca125 combined with ultrasound as a secondary test) and USS (ultrasound alone) compared against a no-screen control group. MMS and USS performed similarly, showing a statistically significant reduction in mortality that increased with follow-up surveillance (8% reduction in years 0-7 vs 28% in years 7-14). The data led to the estimate that 641 screens are needed to prevent one ovarian cancer death.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Kentucky Chandler Medical Center and the Markey Cancer Center, Lexington, KY, USA Epaul1@uky.edu ejpavlik@gmail.com.
Edward J
EJ
Pavlik
D018394:CA-125 Antigen; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008403:Mass Screening; D010051:Ovarian Neoplasms; D014463:Ultrasonography; D006113:United Kingdom
D018394:CA-125 Antigen
efficacy; mortality reduction; ovarian cancer screening; potential for effectiveness; ultrasound